BioAffinity Technologies Stock Forward View - Double Exponential Smoothing
| BIAF Stock | USD 0.85 0.10 13.33% |
BioAffinity Stock outlook is based on your current time horizon. We suggest always using this module together with an analysis of BioAffinity Technologies' historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 9th of February 2026 the rsi of BioAffinity Technologies' share price is below 20 suggesting that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter (2.40) | EPS Estimate Current Year (14.40) | EPS Estimate Next Year (8.10) | Wall Street Target Price 6 | EPS Estimate Current Quarter (2.70) |
Using BioAffinity Technologies hype-based prediction, you can estimate the value of bioAffinity Technologies from the perspective of BioAffinity Technologies response to recently generated media hype and the effects of current headlines on its competitors.
The Double Exponential Smoothing forecasted value of bioAffinity Technologies on the next trading day is expected to be 0.83 with a mean absolute deviation of 0.07 and the sum of the absolute errors of 4.14. BioAffinity Technologies after-hype prediction price | USD 0.88 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
BioAffinity | Build AI portfolio with BioAffinity Stock |
BioAffinity Technologies Additional Predictive Modules
Most predictive techniques to examine BioAffinity price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for BioAffinity using various technical indicators. When you analyze BioAffinity charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
BioAffinity Technologies Double Exponential Smoothing Price Forecast For the 10th of February
Given 90 days horizon, the Double Exponential Smoothing forecasted value of bioAffinity Technologies on the next trading day is expected to be 0.83 with a mean absolute deviation of 0.07, mean absolute percentage error of 0.01, and the sum of the absolute errors of 4.14.Please note that although there have been many attempts to predict BioAffinity Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that BioAffinity Technologies' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
BioAffinity Technologies Stock Forecast Pattern
| Backtest BioAffinity Technologies | BioAffinity Technologies Price Prediction | Research Analysis |
BioAffinity Technologies Forecasted Value
In the context of forecasting BioAffinity Technologies' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. BioAffinity Technologies' downside and upside margins for the forecasting period are 0.01 and 7.20, respectively. We have considered BioAffinity Technologies' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of BioAffinity Technologies stock data series using in forecasting. Note that when a statistical model is used to represent BioAffinity Technologies stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0125 |
| MAD | Mean absolute deviation | 0.0701 |
| MAPE | Mean absolute percentage error | 0.0539 |
| SAE | Sum of the absolute errors | 4.1354 |
Predictive Modules for BioAffinity Technologies
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as bioAffinity Technologies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioAffinity Technologies After-Hype Price Density Analysis
As far as predicting the price of BioAffinity Technologies at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in BioAffinity Technologies or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of BioAffinity Technologies, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
BioAffinity Technologies Estimiated After-Hype Price Volatility
In the context of predicting BioAffinity Technologies' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on BioAffinity Technologies' historical news coverage. BioAffinity Technologies' after-hype downside and upside margins for the prediction period are 0.04 and 7.31, respectively. We have considered BioAffinity Technologies' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
BioAffinity Technologies is dangerous at this time. Analysis and calculation of next after-hype price of bioAffinity Technologies is based on 3 months time horizon.
BioAffinity Technologies Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as BioAffinity Technologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioAffinity Technologies backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with BioAffinity Technologies, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.29 | 6.38 | 0.03 | 69.38 | 8 Events / Month | 5 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.85 | 0.88 | 3.53 |
|
BioAffinity Technologies Hype Timeline
bioAffinity Technologies is currently traded for 0.85. The entity has historical hype elasticity of 0.03, and average elasticity to hype of competition of -69.38. BioAffinity is forecasted to increase in value after the next headline, with the price projected to jump to 0.88 or above. The average volatility of media hype impact on the company the price is over 100%. The price rise on the next news is projected to be 3.53%, whereas the daily expected return is currently at -1.29%. The volatility of related hype on BioAffinity Technologies is about 11.86%, with the expected price after the next announcement by competition of -68.53. bioAffinity Technologies currently holds 1.5 M in liabilities. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Historical Fundamental Analysis of BioAffinity Technologies to cross-verify your projections.BioAffinity Technologies Related Hype Analysis
Having access to credible news sources related to BioAffinity Technologies' direct competition is more important than ever and may enhance your ability to predict BioAffinity Technologies' future price movements. Getting to know how BioAffinity Technologies' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how BioAffinity Technologies may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ARTL | Artelo Biosciences | 0.07 | 7 per month | 0.00 | (0.1) | 7.86 | (10.68) | 41.63 | |
| GTBP | GT Biopharma | 0.01 | 9 per month | 7.79 | 0 | 10.84 | (11.96) | 51.03 | |
| MNDR | Mobile health Network Solutions | (1.03) | 7 per month | 13.16 | (0) | 38.58 | (29.45) | 121.66 | |
| WOK | WORK Medical Technology | (538.00) | 7 per month | 0.00 | (0.21) | 20.48 | (35.75) | 121.00 | |
| CARM | Carisma Therapeutics | 0 | 5 per month | 8.85 | 0.03 | 17.95 | (14.06) | 56.42 | |
| PBM | Psyence Biomedical Ltd | 0.70 | 8 per month | 0.00 | (0.25) | 9.41 | (18.68) | 96.64 | |
| REVB | Revelation Biosciences | 0.19 | 9 per month | 0.00 | (0.26) | 6.84 | (10.16) | 35.57 | |
| PTIX | Protagenic Therapeutics | 0.25 | 3 per month | 0.00 | (0.20) | 14.81 | (18.37) | 58.73 | |
| LIPO | Lipella Pharmaceuticals Common | 0.00 | 1 per month | 0.00 | (0.04) | 17.14 | (21.74) | 94.73 | |
| SLRX | Salarius Pharmaceuticals | (0.02) | 6 per month | 0.00 | (0.19) | 16.00 | (16.92) | 61.05 |
Other Forecasting Options for BioAffinity Technologies
For every potential investor in BioAffinity, whether a beginner or expert, BioAffinity Technologies' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. BioAffinity Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in BioAffinity. Basic forecasting techniques help filter out the noise by identifying BioAffinity Technologies' price trends.BioAffinity Technologies Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioAffinity Technologies stock to make a market-neutral strategy. Peer analysis of BioAffinity Technologies could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
BioAffinity Technologies Market Strength Events
Market strength indicators help investors to evaluate how BioAffinity Technologies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioAffinity Technologies shares will generate the highest return on investment. By undertsting and applying BioAffinity Technologies stock market strength indicators, traders can identify bioAffinity Technologies entry and exit signals to maximize returns.
BioAffinity Technologies Risk Indicators
The analysis of BioAffinity Technologies' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in BioAffinity Technologies' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting bioaffinity stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.79 | |||
| Standard Deviation | 6.35 | |||
| Variance | 40.26 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for BioAffinity Technologies
The number of cover stories for BioAffinity Technologies depends on current market conditions and BioAffinity Technologies' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that BioAffinity Technologies is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about BioAffinity Technologies' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
BioAffinity Technologies Short Properties
BioAffinity Technologies' future price predictability will typically decrease when BioAffinity Technologies' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of bioAffinity Technologies often depends not only on the future outlook of the potential BioAffinity Technologies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioAffinity Technologies' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 404.3 K | |
| Cash And Short Term Investments | 1.1 M |
Check out Historical Fundamental Analysis of BioAffinity Technologies to cross-verify your projections. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Can Biotechnology industry sustain growth momentum? Does BioAffinity have expansion opportunities? Factors like these will boost the valuation of BioAffinity Technologies. Projected growth potential of BioAffinity fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating BioAffinity Technologies demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (13.83) | Revenue Per Share | Quarterly Revenue Growth (0.39) | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioAffinity Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioAffinity Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioAffinity Technologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.